pembrolizumab – Medical News Asia

Cervical Cancer Treatment and Prognosis: Revelations from ESMO 2024 Gynaecological Cancers Congress

16 September 2024/0 Comments/in Oncology In Depth/by Audrey TANG

Cervical cancer (CC) is the 4th most common cancer in women worldwide, with approximately 660,000 new cases in 2022. In Hong Kong, it was the 7th most common cancer among women in 2021, with approximately 600 new cases and 178 deaths. Here we report new findings on CC treatment and prognostic methods from three abstracts published at the annual ESMO Gynaecological Cancer Congress, 20–22 June 2024, Florence, Italy.

Triple-Negative Breast Cancer: Insights from ASCO 2024

10 July 2024/0 Comments/in Therapeutic Areas, Oncology In Depth/by Audrey TANG

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterised by the absence of oestrogen receptors (ER), progesterone receptors, and human epidermal growth factor receptor 2 (HER2) amplification.1,2 Representing about 10–15% of all breast cancer cases, TNBC is associated with poor prognosis and limited treatment options.2 Recent research findings presented at the 2024 American Society of Clinical Oncology (ASCO) meeting provided updates on new advances in the treatment of TNBC.

ASCO 2021 Liver Cancer Update

11 June 2021/in Gastrointestinal Cancer, Oncology, ASCO 2021 Annual Meeting, Chemotherapy, Immunotherapy, Targeted Therapies/by Coco Chong

The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.

Advancing care for advanced renal cell carcinoma: choosing the optimal therapy for you patients

19 April 2021/in Genitourinary Cancer, Oncology, Immunotherapy, Targeted Therapies/by Kirsty LEE

There is no excerpt because this is a protected post.

Breast cancer update January 2021

1 February 2021/in Breast Cancer, Oncology, Chemotherapy, Endocrine Therapy, Radiology, Targeted Therapies, Translational Research/by Kirsty LEE

With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. [‘mediPr] provides you with an overview.

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

8 December 2020/19 Comments/in Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, AE Management, irAE Management/by Stijn van den Borne, MSc

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

7 December 2020/0 Comments/in Gastrointestinal Cancer, Lung Cancer, Oncology, Immunotherapy, Guidelines, Targeted Therapies/by Kirsty LEE

Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancers, and 55% of all HCC cases worldwide are reported from China. In Hong Kong, liver cancer is the fourth most common cancer and the third most common cause of cancer death.

ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717

ASCO 2020 Lung, Breast, and Liver Cancer Update

30 June 2020/0 Comments/in Breast Cancer, China, Conferences, Gastrointestinal Cancer, Lung Cancer, Oncology, ASCO 2020 Annual Meeting, Chemotherapy, Endocrine Therapy, Immunotherapy, Targeted Therapies/by Kirsty LEE

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.

gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

30 April 2020/Enter your password to view comments./in Gastrointestinal Cancer, Oncology, Chemotherapy, Immunotherapy, Surgery, Targeted Therapies, Pathology/by 陳穎樂醫生

There is no excerpt because this is a protected post.

ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

12 June 2019/0 Comments/in Conferences, Lung Cancer, ASCO 2019 Annual Meeting, Oncology, Chemotherapy, Immunotherapy, Radiology, Surgery, Targeted Therapies, Translational Research/by Stijn van den Borne, MSc

Non-small cell lung cancer (NSCLC) was a key feature of the American Society of Clinical Oncology (ASCO) 2019 annual meeting. This year, exciting results with neoadjuvant immunotherapy (I-O) from the LCMC3, NEOSTAR, and GECP16/03_NADIM studies as well as combinations of I-O and PARP-inhibitors with chemoradiation therapy, and more. A summary of 36 oral presentations on NSCLC, SCLC, and Mesothelioma.

Tag Archive for: pembrolizumab